Click for best price
Raibizumab Biosimilars Market Size, Share 2022
Market Analysis and Insights: Global Raibizumab Biosimilars Market
The global Raibizumab Biosimilars market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Raibizumab Biosimilars market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Raibizumab Biosimilars market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Raibizumab Biosimilars market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Raibizumab Biosimilars market.
Global Raibizumab Biosimilars Scope and Market Size
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Segment by Application
- ARMD
- Diabetic Retinopathy
- Macular Edema
By Region
- North America
- United States
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
By Company
- Roche
- Novartis
- Genentech
- Pfizer
- Sartorius
- Eli Lilly
- Bayer
- Amgen
- PlantForm
- PharmaPraxis
- Samsung Bioepis
- Centus
- Cadila Pharmaceuticals
- Dr Reddy's
- Aurobindo Pharma
- Biocad
- MAbxience
- Hetero
- Biocon
- Kirin Biologics
- Mylan
- BeiGene
- Innovent
- Qilu Pharmaceutical
- Hengrui Pharmaceuticals
- Hisun Pharmaceutical
- TOT BIOPHARM
- Luye Pharmaceutical
- Henlius
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes Raibizumab Biosimilars product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of Raibizumab Biosimilars, with price, sales, revenue, and global market share of Raibizumab Biosimilars from 2019 to 2022.
Chapter 3, the Raibizumab Biosimilars competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Raibizumab Biosimilars breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Raibizumab Biosimilars market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Raibizumab Biosimilars.
Chapter 13, 14, and 15, to describe Raibizumab Biosimilars sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 Raibizumab Biosimilars Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global Raibizumab Biosimilars Market Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
117 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Raibizumab Biosimilars Market Overview
1.1 Product Overview and Scope of Raibizumab Biosimilars
1.2 Raibizumab Biosimilars Segment by Type
1.2.1 Global Raibizumab Biosimilars Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 AMD
1.2.3 CNV
1.2.4 DME
1.3 Raibizumab Biosimilars Segment by Application
1.3.1 Global Raibizumab Biosimilars Sales Comparison by Application: (2022-2028)
1.3.2 ARMD
1.3.3 Diabetic Retinopathy
1.3.4 Macular Edema
1.4 Global Raibizumab Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Raibizumab Biosimilars Revenue 2017-2028
1.4.2 Global Raibizumab Biosimilars Sales 2017-2028
1.4.3 Raibizumab Biosimilars Market Size by Region: 2017 Versus 2021 Versus 2028
2 Raibizumab Biosimilars Market Competition by Manufacturers
2.1 Global Raibizumab Biosimilars Sales Market Share by Manufacturers (2017-2022)
2.2 Global Raibizumab Biosimilars Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Raibizumab Biosimilars Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Raibizumab Biosimilars Manufacturing Sites, Area Served, Product Type
2.5 Raibizumab Biosimilars Market Competitive Situation and Trends
2.5.1 Raibizumab Biosimilars Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Raibizumab Biosimilars Players Market Share by Revenue
2.5.3 Global Raibizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Raibizumab Biosimilars Retrospective Market Scenario by Region
3.1 Global Raibizumab Biosimilars Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Raibizumab Biosimilars Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Raibizumab Biosimilars Market Facts & Figures by Country
3.3.1 North America Raibizumab Biosimilars Sales by Country
3.3.2 North America Raibizumab Biosimilars Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Raibizumab Biosimilars Market Facts & Figures by Country
3.4.1 Europe Raibizumab Biosimilars Sales by Country
3.4.2 Europe Raibizumab Biosimilars Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Raibizumab Biosimilars Market Facts & Figures by Region
3.5.1 Asia Pacific Raibizumab Biosimilars Sales by Region
3.5.2 Asia Pacific Raibizumab Biosimilars Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Raibizumab Biosimilars Market Facts & Figures by Country
3.6.1 Latin America Raibizumab Biosimilars Sales by Country
3.6.2 Latin America Raibizumab Biosimilars Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Raibizumab Biosimilars Market Facts & Figures by Country
3.7.1 Middle East and Africa Raibizumab Biosimilars Sales by Country
3.7.2 Middle East and Africa Raibizumab Biosimilars Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Raibizumab Biosimilars Historic Market Analysis by Type
4.1 Global Raibizumab Biosimilars Sales Market Share by Type (2017-2022)
4.2 Global Raibizumab Biosimilars Revenue Market Share by Type (2017-2022)
4.3 Global Raibizumab Biosimilars Price by Type (2017-2022)
5 Global Raibizumab Biosimilars Historic Market Analysis by Application
5.1 Global Raibizumab Biosimilars Sales Market Share by Application (2017-2022)
5.2 Global Raibizumab Biosimilars Revenue Market Share by Application (2017-2022)
5.3 Global Raibizumab Biosimilars Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Roche Raibizumab Biosimilars Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Novartis Raibizumab Biosimilars Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Genentech
6.3.1 Genentech Corporation Information
6.3.2 Genentech Description and Business Overview
6.3.3 Genentech Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Genentech Raibizumab Biosimilars Product Portfolio
6.3.5 Genentech Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Pfizer Raibizumab Biosimilars Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Sartorius
6.5.1 Sartorius Corporation Information
6.5.2 Sartorius Description and Business Overview
6.5.3 Sartorius Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Sartorius Raibizumab Biosimilars Product Portfolio
6.5.5 Sartorius Recent Developments/Updates
6.6 Eli Lilly
6.6.1 Eli Lilly Corporation Information
6.6.2 Eli Lilly Description and Business Overview
6.6.3 Eli Lilly Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Eli Lilly Raibizumab Biosimilars Product Portfolio
6.6.5 Eli Lilly Recent Developments/Updates
6.7 Bayer
6.6.1 Bayer Corporation Information
6.6.2 Bayer Description and Business Overview
6.6.3 Bayer Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Bayer Raibizumab Biosimilars Product Portfolio
6.7.5 Bayer Recent Developments/Updates
6.8 Amgen
6.8.1 Amgen Corporation Information
6.8.2 Amgen Description and Business Overview
6.8.3 Amgen Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Amgen Raibizumab Biosimilars Product Portfolio
6.8.5 Amgen Recent Developments/Updates
6.9 PlantForm
6.9.1 PlantForm Corporation Information
6.9.2 PlantForm Description and Business Overview
6.9.3 PlantForm Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.9.4 PlantForm Raibizumab Biosimilars Product Portfolio
6.9.5 PlantForm Recent Developments/Updates
6.10 PharmaPraxis
6.10.1 PharmaPraxis Corporation Information
6.10.2 PharmaPraxis Description and Business Overview
6.10.3 PharmaPraxis Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.10.4 PharmaPraxis Raibizumab Biosimilars Product Portfolio
6.10.5 PharmaPraxis Recent Developments/Updates
6.11 Samsung Bioepis
6.11.1 Samsung Bioepis Corporation Information
6.11.2 Samsung Bioepis Raibizumab Biosimilars Description and Business Overview
6.11.3 Samsung Bioepis Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Samsung Bioepis Raibizumab Biosimilars Product Portfolio
6.11.5 Samsung Bioepis Recent Developments/Updates
6.12 Centus
6.12.1 Centus Corporation Information
6.12.2 Centus Raibizumab Biosimilars Description and Business Overview
6.12.3 Centus Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Centus Raibizumab Biosimilars Product Portfolio
6.12.5 Centus Recent Developments/Updates
6.13 Cadila Pharmaceuticals
6.13.1 Cadila Pharmaceuticals Corporation Information
6.13.2 Cadila Pharmaceuticals Raibizumab Biosimilars Description and Business Overview
6.13.3 Cadila Pharmaceuticals Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Cadila Pharmaceuticals Raibizumab Biosimilars Product Portfolio
6.13.5 Cadila Pharmaceuticals Recent Developments/Updates
6.14 Dr Reddy's
6.14.1 Dr Reddy's Corporation Information
6.14.2 Dr Reddy's Raibizumab Biosimilars Description and Business Overview
6.14.3 Dr Reddy's Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Dr Reddy's Raibizumab Biosimilars Product Portfolio
6.14.5 Dr Reddy's Recent Developments/Updates
6.15 Aurobindo Pharma
6.15.1 Aurobindo Pharma Corporation Information
6.15.2 Aurobindo Pharma Raibizumab Biosimilars Description and Business Overview
6.15.3 Aurobindo Pharma Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Aurobindo Pharma Raibizumab Biosimilars Product Portfolio
6.15.5 Aurobindo Pharma Recent Developments/Updates
6.16 Biocad
6.16.1 Biocad Corporation Information
6.16.2 Biocad Raibizumab Biosimilars Description and Business Overview
6.16.3 Biocad Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Biocad Raibizumab Biosimilars Product Portfolio
6.16.5 Biocad Recent Developments/Updates
6.17 MAbxience
6.17.1 MAbxience Corporation Information
6.17.2 MAbxience Raibizumab Biosimilars Description and Business Overview
6.17.3 MAbxience Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.17.4 MAbxience Raibizumab Biosimilars Product Portfolio
6.17.5 MAbxience Recent Developments/Updates
6.18 Hetero
6.18.1 Hetero Corporation Information
6.18.2 Hetero Raibizumab Biosimilars Description and Business Overview
6.18.3 Hetero Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.18.4 Hetero Raibizumab Biosimilars Product Portfolio
6.18.5 Hetero Recent Developments/Updates
6.19 Biocon
6.19.1 Biocon Corporation Information
6.19.2 Biocon Raibizumab Biosimilars Description and Business Overview
6.19.3 Biocon Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.19.4 Biocon Raibizumab Biosimilars Product Portfolio
6.19.5 Biocon Recent Developments/Updates
6.20 Kirin Biologics
6.20.1 Kirin Biologics Corporation Information
6.20.2 Kirin Biologics Raibizumab Biosimilars Description and Business Overview
6.20.3 Kirin Biologics Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.20.4 Kirin Biologics Raibizumab Biosimilars Product Portfolio
6.20.5 Kirin Biologics Recent Developments/Updates
6.21 Mylan
6.21.1 Mylan Corporation Information
6.21.2 Mylan Raibizumab Biosimilars Description and Business Overview
6.21.3 Mylan Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.21.4 Mylan Raibizumab Biosimilars Product Portfolio
6.21.5 Mylan Recent Developments/Updates
6.22 BeiGene
6.22.1 BeiGene Corporation Information
6.22.2 BeiGene Raibizumab Biosimilars Description and Business Overview
6.22.3 BeiGene Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.22.4 BeiGene Raibizumab Biosimilars Product Portfolio
6.22.5 BeiGene Recent Developments/Updates
6.23 Innovent
6.23.1 Innovent Corporation Information
6.23.2 Innovent Raibizumab Biosimilars Description and Business Overview
6.23.3 Innovent Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.23.4 Innovent Raibizumab Biosimilars Product Portfolio
6.23.5 Innovent Recent Developments/Updates
6.24 Qilu Pharmaceutical
6.24.1 Qilu Pharmaceutical Corporation Information
6.24.2 Qilu Pharmaceutical Raibizumab Biosimilars Description and Business Overview
6.24.3 Qilu Pharmaceutical Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.24.4 Qilu Pharmaceutical Raibizumab Biosimilars Product Portfolio
6.24.5 Qilu Pharmaceutical Recent Developments/Updates
6.25 Hengrui Pharmaceuticals
6.25.1 Hengrui Pharmaceuticals Corporation Information
6.25.2 Hengrui Pharmaceuticals Raibizumab Biosimilars Description and Business Overview
6.25.3 Hengrui Pharmaceuticals Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.25.4 Hengrui Pharmaceuticals Raibizumab Biosimilars Product Portfolio
6.25.5 Hengrui Pharmaceuticals Recent Developments/Updates
6.26 Hisun Pharmaceutical
6.26.1 Hisun Pharmaceutical Corporation Information
6.26.2 Hisun Pharmaceutical Raibizumab Biosimilars Description and Business Overview
6.26.3 Hisun Pharmaceutical Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.26.4 Hisun Pharmaceutical Raibizumab Biosimilars Product Portfolio
6.26.5 Hisun Pharmaceutical Recent Developments/Updates
6.27 TOT BIOPHARM
6.27.1 TOT BIOPHARM Corporation Information
6.27.2 TOT BIOPHARM Raibizumab Biosimilars Description and Business Overview
6.27.3 TOT BIOPHARM Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.27.4 TOT BIOPHARM Raibizumab Biosimilars Product Portfolio
6.27.5 TOT BIOPHARM Recent Developments/Updates
6.28 Luye Pharmaceutical
6.28.1 Luye Pharmaceutical Corporation Information
6.28.2 Luye Pharmaceutical Raibizumab Biosimilars Description and Business Overview
6.28.3 Luye Pharmaceutical Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.28.4 Luye Pharmaceutical Raibizumab Biosimilars Product Portfolio
6.28.5 Luye Pharmaceutical Recent Developments/Updates
6.29 Henlius
6.29.1 Henlius Corporation Information
6.29.2 Henlius Raibizumab Biosimilars Description and Business Overview
6.29.3 Henlius Raibizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.29.4 Henlius Raibizumab Biosimilars Product Portfolio
6.29.5 Henlius Recent Developments/Updates
7 Raibizumab Biosimilars Manufacturing Cost Analysis
7.1 Raibizumab Biosimilars Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Raibizumab Biosimilars
7.4 Raibizumab Biosimilars Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Raibizumab Biosimilars Distributors List
8.3 Raibizumab Biosimilars Customers
9 Raibizumab Biosimilars Market Dynamics
9.1 Raibizumab Biosimilars Industry Trends
9.2 Raibizumab Biosimilars Market Drivers
9.3 Raibizumab Biosimilars Market Challenges
9.4 Raibizumab Biosimilars Market Restraints
10 Global Market Forecast
10.1 Raibizumab Biosimilars Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Raibizumab Biosimilars by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Raibizumab Biosimilars by Type (2023-2028)
10.2 Raibizumab Biosimilars Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Raibizumab Biosimilars by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Raibizumab Biosimilars by Application (2023-2028)
10.3 Raibizumab Biosimilars Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Raibizumab Biosimilars by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Raibizumab Biosimilars by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Global Raibizumab Biosimilars Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Raibizumab Biosimilars Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Raibizumab Biosimilars Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Raibizumab Biosimilars Market Competitive Situation by Manufacturers in 2021
Table 5. Global Raibizumab Biosimilars Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Raibizumab Biosimilars Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Raibizumab Biosimilars Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Raibizumab Biosimilars Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Raibizumab Biosimilars Average Price (K USD/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Raibizumab Biosimilars Manufacturing Sites and Area Served
Table 11. Manufacturers Raibizumab Biosimilars Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Raibizumab Biosimilars by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Raibizumab Biosimilars as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Raibizumab Biosimilars Sales by Region (2017-2022) & (K Units)
Table 16. Global Raibizumab Biosimilars Sales Market Share by Region (2017-2022)
Table 17. Global Raibizumab Biosimilars Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Raibizumab Biosimilars Revenue Market Share by Region (2017-2022)
Table 19. North America Raibizumab Biosimilars Sales by Country (2017-2022) & (K Units)
Table 20. North America Raibizumab Biosimilars Sales Market Share by Country (2017-2022)
Table 21. North America Raibizumab Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Raibizumab Biosimilars Revenue Market Share by Country (2017-2022)
Table 23. Europe Raibizumab Biosimilars Sales by Country (2017-2022) & (K Units)
Table 24. Europe Raibizumab Biosimilars Sales Market Share by Country (2017-2022)
Table 25. Europe Raibizumab Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Raibizumab Biosimilars Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Raibizumab Biosimilars Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Raibizumab Biosimilars Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Raibizumab Biosimilars Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Raibizumab Biosimilars Revenue Market Share by Region (2017-2022)
Table 31. Latin America Raibizumab Biosimilars Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Raibizumab Biosimilars Sales Market Share by Country (2017-2022)
Table 33. Latin America Raibizumab Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Raibizumab Biosimilars Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Raibizumab Biosimilars Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Raibizumab Biosimilars Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Raibizumab Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Raibizumab Biosimilars Revenue Market Share by Country (2017-2022)
Table 39. Global Raibizumab Biosimilars Sales by Type (2017-2022) & (K Units)
Table 40. Global Raibizumab Biosimilars Sales Market Share by Type (2017-2022)
Table 41. Global Raibizumab Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Raibizumab Biosimilars Revenue Share by Type (2017-2022)
Table 43. Global Raibizumab Biosimilars Price by Type (2017-2022) & (K USD/Unit)
Table 44. Global Raibizumab Biosimilars Sales (K Units) by Application (2017-2022)
Table 45. Global Raibizumab Biosimilars Sales Market Share by Application (2017-2022)
Table 46. Global Raibizumab Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Raibizumab Biosimilars Revenue Share by Application (2017-2022)
Table 48. Global Raibizumab Biosimilars Price by Application (2017-2022) & (K USD/Unit)
Table 49. Roche Corporation Information
Table 50. Roche Description and Business Overview
Table 51. Roche Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 52. Roche Raibizumab Biosimilars Product
Table 53. Roche Recent Developments/Updates
Table 54. Novartis Corporation Information
Table 55. Novartis Description and Business Overview
Table 56. Novartis Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 57. Novartis Raibizumab Biosimilars Product
Table 58. Novartis Recent Developments/Updates
Table 59. Genentech Corporation Information
Table 60. Genentech Description and Business Overview
Table 61. Genentech Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 62. Genentech Raibizumab Biosimilars Product
Table 63. Genentech Recent Developments/Updates
Table 64. Pfizer Corporation Information
Table 65. Pfizer Description and Business Overview
Table 66. Pfizer Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 67. Pfizer Raibizumab Biosimilars Product
Table 68. Pfizer Recent Developments/Updates
Table 69. Sartorius Corporation Information
Table 70. Sartorius Description and Business Overview
Table 71. Sartorius Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 72. Sartorius Raibizumab Biosimilars Product
Table 73. Sartorius Recent Developments/Updates
Table 74. Eli Lilly Corporation Information
Table 75. Eli Lilly Description and Business Overview
Table 76. Eli Lilly Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 77. Eli Lilly Raibizumab Biosimilars Product
Table 78. Eli Lilly Recent Developments/Updates
Table 79. Bayer Corporation Information
Table 80. Bayer Description and Business Overview
Table 81. Bayer Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 82. Bayer Raibizumab Biosimilars Product
Table 83. Bayer Recent Developments/Updates
Table 84. Amgen Corporation Information
Table 85. Amgen Description and Business Overview
Table 86. Amgen Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 87. Amgen Raibizumab Biosimilars Product
Table 88. Amgen Recent Developments/Updates
Table 89. PlantForm Corporation Information
Table 90. PlantForm Description and Business Overview
Table 91. PlantForm Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 92. PlantForm Raibizumab Biosimilars Product
Table 93. PlantForm Recent Developments/Updates
Table 94. PharmaPraxis Corporation Information
Table 95. PharmaPraxis Description and Business Overview
Table 96. PharmaPraxis Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 97. PharmaPraxis Raibizumab Biosimilars Product
Table 98. PharmaPraxis Recent Developments/Updates
Table 99. Samsung Bioepis Corporation Information
Table 100. Samsung Bioepis Description and Business Overview
Table 101. Samsung Bioepis Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 102. Samsung Bioepis Raibizumab Biosimilars Product
Table 103. Samsung Bioepis Recent Developments/Updates
Table 104. Centus Corporation Information
Table 105. Centus Description and Business Overview
Table 106. Centus Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 107. Centus Raibizumab Biosimilars Product
Table 108. Centus Recent Developments/Updates
Table 109. Cadila Pharmaceuticals Corporation Information
Table 110. Cadila Pharmaceuticals Description and Business Overview
Table 111. Cadila Pharmaceuticals Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 112. Cadila Pharmaceuticals Raibizumab Biosimilars Product
Table 113. Cadila Pharmaceuticals Recent Developments/Updates
Table 114. Dr Reddy's Corporation Information
Table 115. Dr Reddy's Description and Business Overview
Table 116. Dr Reddy's Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 117. Dr Reddy's Raibizumab Biosimilars Product
Table 118. Dr Reddy's Recent Developments/Updates
Table 119. Aurobindo Pharma Corporation Information
Table 120. Aurobindo Pharma Description and Business Overview
Table 121. Aurobindo Pharma Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 122. Aurobindo Pharma Raibizumab Biosimilars Product
Table 123. Aurobindo Pharma Recent Developments/Updates
Table 124. Biocad Corporation Information
Table 125. Biocad Description and Business Overview
Table 126. Biocad Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 127. Biocad Raibizumab Biosimilars Product
Table 128. Biocad Recent Developments/Updates
Table 129. MAbxience Corporation Information
Table 130. MAbxience Description and Business Overview
Table 131. MAbxience Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 132. MAbxience Raibizumab Biosimilars Product
Table 133. MAbxience Recent Developments/Updates
Table 134. Hetero Corporation Information
Table 135. Hetero Description and Business Overview
Table 136. Hetero Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 137. Hetero Raibizumab Biosimilars Product
Table 138. Hetero Recent Developments/Updates
Table 139. Biocon Corporation Information
Table 140. Biocon Description and Business Overview
Table 141. Biocon Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 142. Biocon Raibizumab Biosimilars Product
Table 143. Biocon Recent Developments/Updates
Table 144. Kirin Biologics Corporation Information
Table 145. Kirin Biologics Description and Business Overview
Table 146. Kirin Biologics Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 147. Kirin Biologics Raibizumab Biosimilars Product
Table 148. Kirin Biologics Recent Developments/Updates
Table 149. Mylan Corporation Information
Table 150. Mylan Description and Business Overview
Table 151. Mylan Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 152. Mylan Raibizumab Biosimilars Product
Table 153. Mylan Recent Developments/Updates
Table 154. BeiGene Corporation Information
Table 155. BeiGene Description and Business Overview
Table 156. BeiGene Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 157. BeiGene Raibizumab Biosimilars Product
Table 158. BeiGene Recent Developments/Updates
Table 159. Innovent Corporation Information
Table 160. Innovent Description and Business Overview
Table 161. Innovent Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 162. Innovent Raibizumab Biosimilars Product
Table 163. Innovent Recent Developments/Updates
Table 164. Qilu Pharmaceutical Corporation Information
Table 165. Qilu Pharmaceutical Description and Business Overview
Table 166. Qilu Pharmaceutical Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 167. Qilu Pharmaceutical Raibizumab Biosimilars Product
Table 168. Qilu Pharmaceutical Recent Developments/Updates
Table 169. Hengrui Pharmaceuticals Corporation Information
Table 170. Hengrui Pharmaceuticals Description and Business Overview
Table 171. Hengrui Pharmaceuticals Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 172. Hengrui Pharmaceuticals Raibizumab Biosimilars Product
Table 173. Hengrui Pharmaceuticals Recent Developments/Updates
Table 174. Hisun Pharmaceutical Corporation Information
Table 175. Hisun Pharmaceutical Description and Business Overview
Table 176. Hisun Pharmaceutical Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 177. Hisun Pharmaceutical Raibizumab Biosimilars Product
Table 178. Hisun Pharmaceutical Recent Developments/Updates
Table 179. TOT BIOPHARM Corporation Information
Table 180. TOT BIOPHARM Description and Business Overview
Table 181. TOT BIOPHARM Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 182. TOT BIOPHARM Raibizumab Biosimilars Product
Table 183. TOT BIOPHARM Recent Developments/Updates
Table 184. Luye Pharmaceutical Corporation Information
Table 185. Luye Pharmaceutical Description and Business Overview
Table 186. Luye Pharmaceutical Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 187. Luye Pharmaceutical Raibizumab Biosimilars Product
Table 188. Luye Pharmaceutical Recent Developments/Updates
Table 189. Henlius Corporation Information
Table 190. Henlius Description and Business Overview
Table 191. Henlius Raibizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 192. Henlius Raibizumab Biosimilars Product
Table 193. Henlius Recent Developments/Updates
Table 194. Production Base and Market Concentration Rate of Raw Material
Table 195. Key Suppliers of Raw Materials
Table 196. Raibizumab Biosimilars Distributors List
Table 197. Raibizumab Biosimilars Customers List
Table 198. Raibizumab Biosimilars Market Trends
Table 199. Raibizumab Biosimilars Market Drivers
Table 200. Raibizumab Biosimilars Market Challenges
Table 201. Raibizumab Biosimilars Market Restraints
Table 202. Global Raibizumab Biosimilars Sales Forecast by Type (2023-2028) & (K Units)
Table 203. Global Raibizumab Biosimilars Sales Market Share Forecast by Type (2023-2028)
Table 204. Global Raibizumab Biosimilars Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 205. Global Raibizumab Biosimilars Revenue Market Share Forecast by Type (2023-2028)
Table 206. Global Raibizumab Biosimilars Sales Forecast by Application (2023-2028) & (K Units)
Table 207. Global Raibizumab Biosimilars Sales Market Share Forecast by Application (2023-2028)
Table 208. Global Raibizumab Biosimilars Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 209. Global Raibizumab Biosimilars Revenue Market Share Forecast by Application (2023-2028)
Table 210. Global Raibizumab Biosimilars Sales Forecast by Region (2023-2028) & (K Units)
Table 211. Global Raibizumab Biosimilars Sales Market Share Forecast by Region (2023-2028)
Table 212. Global Raibizumab Biosimilars Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 213. Global Raibizumab Biosimilars Revenue Market Share Forecast by Region (2023-2028)
Table 214. Research Programs/Design for This Report
Table 215. Key Data Information from Secondary Sources
Table 216. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Raibizumab Biosimilars
Figure 2. Global Raibizumab Biosimilars Market Share by Type in 2021 & 2028
Figure 3. AMD Product Picture
Figure 4. CNV Product Picture
Figure 5. DME Product Picture
Figure 6. Global Raibizumab Biosimilars Market Share by Application in 2021 & 2028
Figure 7. ARMD
Figure 8. Diabetic Retinopathy
Figure 9. Macular Edema
Figure 10. Global Raibizumab Biosimilars Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Raibizumab Biosimilars Market Size (2017-2028) & (US$ Million)
Figure 12. Global Raibizumab Biosimilars Sales (2017-2028) & (K Units)
Figure 13. Raibizumab Biosimilars Sales Share by Manufacturers in 2021
Figure 14. Global Raibizumab Biosimilars Revenue Share by Manufacturers in 2021
Figure 15. The Global 5 and 10 Largest Raibizumab Biosimilars Players: Market Share by Revenue in 2021
Figure 16. Raibizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 17. Global Raibizumab Biosimilars Sales Market Share by Region (2017-2022)
Figure 18. Global Raibizumab Biosimilars Sales Market Share by Region in 2021
Figure 19. Global Raibizumab Biosimilars Revenue Market Share by Region (2017-2022)
Figure 20. Global Raibizumab Biosimilars Revenue Market Share by Region in 2021
Figure 21. United States Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. Canada Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. Germany Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. France Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. U.K. Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. Italy Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Russia Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. China Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. Japan Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. South Korea Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. India Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Australia Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. China Taiwan Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Indonesia Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Thailand Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Malaysia Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Mexico Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Brazil Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Argentina Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Turkey Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Saudi Arabia Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. UAE Raibizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Sales Market Share of Raibizumab Biosimilars by Type (2017-2022)
Figure 44. Manufacturing Cost Structure of Raibizumab Biosimilars
Figure 45. Manufacturing Process Analysis of Raibizumab Biosimilars
Figure 46. Raibizumab Biosimilars Industrial Chain Analysis
Figure 47. Channels of Distribution
Figure 48. Distributors Profiles
Figure 49. Bottom-up and Top-down Approaches for This Report
Figure 50. Data Triangulation
Figure 51. Key Executives Interviewed
